The United Kingdom is significantly advancing the treatment of Type 2 diabetes. New guidance from the National Institute for Health and Care Excellence (NICE) now recommends sodium-glucose co-transporter 2 (SGLT-2) inhibitors much earlier in the treatment process. This shift is projected to prevent approximately 17,000 deaths across the UK over a three-year period by mitigating risks of heart attacks, strokes, and kidney complications.
Previously, metformin served as the standard first-line treatment. The updated recommendation positions metformin alongside an SGLT-2 inhibitor as the initial approach. Clinical trials demonstrate that SGLT-2 inhibitors not only lower blood sugar but also offer crucial protective benefits for the heart and kidneys, thereby reducing the likelihood of premature death from cardiac events.
Further enhancing this development, a generic version of dapagliflozin, a widely prescribed SGLT-2 inhibitor, is now available. This is anticipated to generate substantial savings for the National Health Service (NHS).
Analysis of UK primary care data, involving 60,000 individuals, indicated that patients prescribed SGLT-2 inhibitors were 24% less likely to experience premature death over three years compared to those on alternative treatments.
The guidance also emphasizes a patient-centered approach, ensuring the treatment is tailored to individual needs. Healthcare professionals are advised to assess heart and kidney health before initiating therapy and introduce new medications incrementally. Specific patient groups, including those diagnosed before age 40, individuals with obesity, and those with pre-existing kidney disease or heart failure, will benefit from tailored strategies, potentially including GLP-1 receptor agonists or tirzepatide. Semaglutide will also be recommended for patients with Type 2 diabetes and cardiovascular disease linked to blocked arteries.